Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids*

When grown as three-dimensional structures, tumor cells can acquire an additional multicellular resistance to apoptosis that may mimic the chemoresistance found in solid tumors. We developed a multicellular spheroid model of malignant mesothelioma to investigate molecular mechanisms of acquired apoptotic resistance. We found that mesothelioma cell lines, when grown as multicellular spheroids, acquired resistance to a variety of apoptotic stimuli, including combinations of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), ribotoxic stressors, histone deacetylase, and proteasome inhibitors, that were highly effective against mesothelioma cells when grown as monolayers. Inhibitors of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway, particularly rapamycin, blocked much of the acquired resistance of the spheroids, suggesting a key role for mTOR. Knockdown by small interference RNA of S6K, a major downstream target of mTOR, reproduced the effect of rapamycin, thereby confirming the role of mTOR and of S6K in the acquired resistance of threedimensional spheroids. Rapamycin or S6K knockdown increased TRAIL-induced caspase-8 cleavage in spheroids, suggesting initially that mTOR inhibited apoptosis by actions at the death receptor pathway; however, isolation of the apoptotic pathways by means of Bid knockdown ablated this effect showing that mTOR actually controls a step distal to Bid, probably at the level of the mitochondria. In sum, mTOR and S6K contribute to the apoptotic resistance of mesothelioma cells in three-dimensional, not in two-dimensional, cultures. The three-dimensional model may reflect a more clinically relevant in vitro setting in which mTOR exhibits anti-apoptotic properties.

[1]  R. Knüchel,et al.  Importance of tyrosine phosphatases in the effects of cell‐cell contact and microenvironments on EGF‐stimulated tyrosine phosphorylation , 1992, Journal of cellular physiology.

[2]  M Intaglietta,et al.  Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C. Larabell,et al.  Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[5]  JONG BIN Kim,et al.  Three-dimensional tissue culture models in cancer biology. , 2005, Seminars in cancer biology.

[6]  Benjamin R. Myers,et al.  FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Radisky,et al.  Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells , 2004, The Journal of cell biology.

[8]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[9]  H. Mizusawa,et al.  Detection and tentative identification of dominant mycoplasma species in cell cultures by restriction analysis of the 16S-23S rRNA intergenic spacer regions. , 1993, Research in microbiology.

[10]  C. Porta,et al.  Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma , 2007, Clinical Cancer Research.

[11]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[12]  H. Lane,et al.  The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.

[13]  K. Guan,et al.  Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? , 2006, Oncogene.

[14]  M. Mann,et al.  p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Ivascu,et al.  Rapid Generation of Single-Tumor Spheroids for High-Throughput Cell Function and Toxicity Analysis , 2006, Journal of biomolecular screening.

[16]  G. Evan,et al.  Bid Mediates Apoptotic Synergy between Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage* , 2005, Journal of Biological Chemistry.

[17]  D. Schrump,et al.  Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade , 2006, Apoptosis.

[18]  J. Testa,et al.  AKT signaling in normal and malignant cells , 2005, Oncogene.

[19]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[20]  Keiran S. M. Smalley,et al.  Life ins't flat: Taking cancer biology to the next dimension , 2006, In Vitro Cellular & Developmental Biology - Animal.

[21]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[22]  V. Broaddus,et al.  c-Jun N-terminal Kinase Contributes to Apoptotic Synergy Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand plus DNA Damage in Chemoresistant, p53 Inactive Mesothelioma Cells* , 2003, Journal of Biological Chemistry.

[23]  M. Murakami,et al.  Distinct Signaling Events Downstream of mTOR Cooperate To Mediate the Effects of Amino Acids and Insulin on Initiation Factor 4E-Binding Proteins , 2005, Molecular and Cellular Biology.

[24]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[25]  G. Fracasso,et al.  Effect of therapeutic macromolecules in spheroids. , 2000, Critical reviews in oncology/hematology.

[26]  L. Helman,et al.  Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.

[27]  J. Jardillier,et al.  Multicellular resistance: a paradigm for clinical resistance? , 2000, Critical reviews in oncology/hematology.

[28]  S. Lowe,et al.  Reversing Drug Resistance In Vivo , 2004, Cell cycle.

[29]  S. Lowe,et al.  Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. , 2006, Cancer research.

[30]  G. Evan,et al.  Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim , 2007, Molecular Cancer Therapeutics.

[31]  J. Neuzil,et al.  Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. , 2004, Biochemical and biophysical research communications.

[32]  C. Thompson,et al.  Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. , 2003, Cancer research.

[33]  D. Fennell,et al.  Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. , 2004, The Lancet. Oncology.

[34]  A. Strasser,et al.  The BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell-Cycle Arrest , 2007, Cell.

[35]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[36]  C. Michael,et al.  Confocal laser scanning microscopy and three‐dimensional reconstruction of cell clusters in serous fluids , 1997, Diagnostic cytopathology.

[37]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[38]  F. Pampaloni,et al.  The third dimension bridges the gap between cell culture and live tissue , 2007, Nature Reviews Molecular Cell Biology.

[39]  R. Vento,et al.  Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of β-catenin, pRb and Bcl-XL , 2004 .

[40]  Huajun Yan,et al.  Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.

[41]  Maria Teresa Santini,et al.  Three-Dimensional Spheroid Model in Tumor Biology , 1999, Pathobiology.

[42]  M. Berger,et al.  mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells , 2005, Molecular and Cellular Biology.

[43]  A. Gingras,et al.  Translational Homeostasis: Eukaryotic Translation Initiation Factor 4E Control of 4E-Binding Protein 1 and p70 S6 Kinase Activities , 1999, Molecular and Cellular Biology.

[44]  A. Klabatsa,et al.  Chemotherapy options and new advances in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  D. Sabatini,et al.  Stress and mTORture signaling , 2006, Oncogene.

[46]  G. Rosen,et al.  Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. , 2001, American journal of respiratory cell and molecular biology.

[47]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[48]  D. Whitaker Cell aggregates in malignant mesothelioma. , 1977, Acta cytologica.

[49]  D. Jablons,et al.  A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. , 2005, American journal of respiratory cell and molecular biology.

[50]  G. Thomas,et al.  mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. , 2007, Trends in molecular medicine.

[51]  Anthony P. Napolitano,et al.  Dynamics of the self-assembly of complex cellular aggregates on micromolded nonadhesive hydrogels. , 2007, Tissue engineering.

[52]  C. Hauser,et al.  Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. , 2005, Cancer research.

[53]  T. Finkel,et al.  Mitochondrial signaling, TOR, and life span , 2006, Biological chemistry.

[54]  Kenneth M. Yamada,et al.  Taking Cell-Matrix Adhesions to the Third Dimension , 2001, Science.

[55]  J. Ernst,et al.  Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. , 1996, The Journal of clinical investigation.

[56]  P. Houghton,et al.  mTOR and cancer therapy , 2006, Oncogene.

[57]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[58]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[59]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[60]  S. Jhanwar,et al.  Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth , 2005, Oncogene.

[61]  G. Thomas,et al.  The amino acid sensitive TOR pathway from yeast to mammals , 2006, FEBS letters.

[62]  M. Bjornsti,et al.  TOR Signaling Is a Determinant of Cell Survival in Response to DNA Damage , 2007, Molecular and Cellular Biology.

[63]  C. Porta,et al.  SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. , 2005, Cancer research.

[64]  Ronald N Germain,et al.  Modeling T Cell Antigen Discrimination Based on Feedback Control of Digital ERK Responses , 2005, PLoS biology.